Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy wins approval for generic analgesics

India-headquartered Ranbaxy Pharmaceuticals (RPI) has won FDA approval to manufacture and market two analgesic drugs.

India-headquartered Ranbaxy Pharmaceuticals (RPI) has won FDA approval to manufacture and market two analgesic drugs.

The FDA approval permits Ranbaxy to produce different dosages of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain.

The approved drugs are bio-equivalent copies of Norco, Vicodin and Lortab, the annual market sales of which were USD 391m.

Jim Meehan, vice-president of sales and marketing for RPI, said: "These approvals further expand our product portfolio of affordable generic alternatives and will be launched in a November 2007 time period."

21st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics